

# Tatsuya Fukuta

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1858521/publications.pdf>

Version: 2024-02-01

48  
papers

972  
citations

471509

17  
h-index

454955

30  
g-index

51  
all docs

51  
docs citations

51  
times ranked

1151  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effective Anticancer Therapy by Combination of Nanoparticles Encapsulating Chemotherapeutic Agents and Weak Electric Current. <i>Biological and Pharmaceutical Bulletin</i> , 2022, 45, 194-199.	1.4	5
2	Application and Utility of Liposomal Neuroprotective Agents and Biomimetic Nanoparticles for the Treatment of Ischemic Stroke. <i>Pharmaceutics</i> , 2022, 14, 361.	4.5	17
3	Iontophoresis-mediated direct delivery of nucleic acid therapeutics, without use of carriers, to internal organs via non-blood circulatory pathways. <i>Journal of Controlled Release</i> , 2022, 343, 392-399.	9.9	9
4	Biomimetic Nanoparticle Drug Delivery Systems to Overcome Biological Barriers for Therapeutic Applications. <i>Chemical and Pharmaceutical Bulletin</i> , 2022, 70, 334-340.	1.3	7
5	Enhancement of cerebroprotective effects of lipid nanoparticles encapsulating FK506 on cerebral ischemia/reperfusion injury by particle size regulation. <i>Biochemical and Biophysical Research Communications</i> , 2022, 611, 53-59.	2.1	2
6	Suppression of Lipid Accumulation in 3T3-L1 Adipocytes by $\hat{\alpha}$ -Tocopheryl Succinate. <i>Biological and Pharmaceutical Bulletin</i> , 2021, 44, 46-50.	1.4	3
7	Leukocyte-Mimetic Liposomes Penetrate Into Tumor Spheroids and Suppress Spheroid Growth by Encapsulated Doxorubicin. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 1701-1709.	3.3	10
8	Overcoming thickened pathological skin in psoriasis via iontophoresis combined with tight junction-opening peptide AT1002 for intradermal delivery of NF- $\hat{\kappa}$ B decoy oligodeoxynucleotide. <i>International Journal of Pharmaceutics</i> , 2021, 602, 120601.	5.2	9
9	Development of a novel antioxidant based on a dimeric dihydroisocoumarin derivative. <i>Tetrahedron Letters</i> , 2021, 74, 153176.	1.4	0
10	A simple, fast, and orientation-controllable technology for preparing antibody-modified liposomes. <i>International Journal of Pharmaceutics</i> , 2021, 607, 120966.	5.2	5
11	Development of Biomembrane-mimetic Nanoparticles to Overcome Endothelial Cell Layer for Treating Ischemic Stroke. <i>Membrane</i> , 2021, 46, 306-311.	0.0	0
12	Transdermal drug delivery by iontophoresis. <i>Drug Delivery System</i> , 2021, 36, 198-208.	0.0	1
13	Enhancement of antioxidative activity of astaxanthin by combination with an antioxidant capable of forming intermolecular interactions. <i>Free Radical Research</i> , 2020, 54, 818-828.	3.3	7
14	Characteristics of unique endocytosis induced by weak current for cytoplasmic drug delivery. <i>International Journal of Pharmaceutics</i> , 2020, 576, 119010.	5.2	11
15	Low level electricity increases the secretion of extracellular vesicles from cultured cells. <i>Biochemistry and Biophysics Reports</i> , 2020, 21, 100713.	1.3	34
16	Release rate is a key variable affecting the therapeutic effectiveness of liposomal fasudil for the treatment of cerebral ischemia/reperfusion injury. <i>Biochemical and Biophysical Research Communications</i> , 2020, 531, 622-627.	2.1	4
17	Protective effect of high-affinity liposomes encapsulating astaxanthin against corneal disorder in the <i>in vivo</i> rat dry eye disease model. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2020, 66, 224-232.	1.4	14
18	Noninvasive transdermal delivery of liposomes by weak electric current. <i>Advanced Drug Delivery Reviews</i> , 2020, 154-155, 227-235.	13.7	31

#	ARTICLE	IF	CITATIONS
19	Non-invasive delivery of biological macromolecular drugs into the skin by iontophoresis and its application to psoriasis treatment. <i>Journal of Controlled Release</i> , 2020, 323, 323-332.	9.9	39
20	Protective Effect of Antioxidative Liposomes Co-encapsulating Astaxanthin and Capsaicin on CCl <sub>4</sub> -Induced Liver Injury. <i>Biological and Pharmaceutical Bulletin</i> , 2020, 43, 1272-1274.	1.4	2
21	Weak Electric Current Treatment to Artificially Enhance Vascular Permeability in Embryonated Chicken Eggs. <i>Biological and Pharmaceutical Bulletin</i> , 2020, 43, 1729-1734.	1.4	1
22	Gut microbial metabolites of linoleic acid are metabolized by accelerated peroxisomal $\beta$ -oxidation in mammalian cells. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2019, 1864, 1619-1628.	2.4	7
23	Glycosylinositol phosphoceramide-specific phospholipase D activity catalyzes transphosphatidylation. <i>Journal of Biochemistry</i> , 2019, 166, 441-448.	1.7	8
24	Biological Functions of $\alpha$ -Tocopheryl Succinate. <i>Journal of Nutritional Science and Vitaminology</i> , 2019, 65, S104-S108.	0.6	6
25	Engineering the Binding Kinetics of Synthetic Polymer Nanoparticles for siRNA Delivery. <i>Biomacromolecules</i> , 2019, 20, 3648-3657.	5.4	12
26	Suppression of Cerebral Ischemia/Reperfusion Injury by Efficient Release of Encapsulated Ifenprodil From Liposomes Under Weakly Acidic pH Conditions. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 3823-3830.	3.3	5
27	Applications of Liposomal Drug Delivery Systems to Develop Neuroprotective Agents for the Treatment of Ischemic Stroke. <i>Biological and Pharmaceutical Bulletin</i> , 2019, 42, 319-326.	1.4	33
28	Leukocyte-mimetic liposomes possessing leukocyte membrane proteins pass through inflamed endothelial cell layer by regulating intercellular junctions. <i>International Journal of Pharmaceutics</i> , 2019, 563, 314-323.	5.2	14
29	Efficacy of high-affinity liposomal astaxanthin on up-regulation of age-related markers induced by oxidative stress in human corneal epithelial cells. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2019, 64, 27-35.	1.4	21
30	Quantitative Analysis of Glycosylinositol Phosphoceramide and Phytoceramide 1-Phosphate in Vegetables. <i>Journal of Nutritional Science and Vitaminology</i> , 2019, 65, S175-S179.	0.6	4
31	Lysophosphatidic acid in medicinal herbs enhances prostaglandin E <sub>2</sub> and protects against indomethacin-induced gastric cell damage in vivo and in vitro. <i>Prostaglandins and Other Lipid Mediators</i> , 2018, 135, 36-44.	1.9	16
32	Co-administration of liposomal fasudil and tissue plasminogen activator ameliorated ischemic brain damage in occlusion model rats prepared by photochemically induced thrombosis. <i>Biochemical and Biophysical Research Communications</i> , 2018, 495, 873-877.	2.1	20
33	Carotenoid Stereochemistry Affects Antioxidative Activity of Liposomes Co-encapsulating Astaxanthin and Tocotrienol. <i>Chemical and Pharmaceutical Bulletin</i> , 2018, 66, 714-720.	1.3	4
34	Combination therapy with liposomal neuroprotectants and tissue plasminogen activator for treatment of ischemic stroke. <i>FASEB Journal</i> , 2017, 31, 1879-1890.	0.5	88
35	Targeted delivery of anticancer drugs to tumor vessels by use of liposomes modified with a peptide identified by phage biopanning with human endothelial progenitor cells. <i>International Journal of Pharmaceutics</i> , 2017, 524, 364-372.	5.2	23
36	Usefulness of Liposomal Neuroprotectants for the Treatment of Ischemic Stroke. <i>Oleoscience</i> , 2017, 17, 359-366.	0.0	0

#	ARTICLE	IF	CITATIONS
37	Targeted Therapy for Acute Autoimmune Myocarditis with Nano-Sized Liposomal FK506 in Rats. PLoS ONE, 2016, 11, e0160944.	2.5	14
38	Neuroprotection against cerebral ischemia/reperfusion injury by intravenous administration of liposomal fasudil. International Journal of Pharmaceutics, 2016, 506, 129-137.	5.2	58
39	Non-invasive evaluation of neuroprotective drug candidates for cerebral infarction by PET imaging of mitochondrial complex-I activity. Scientific Reports, 2016, 6, 30127.	3.3	13
40	Development of a liposomal drug delivery system for the treatment of ischemic stroke. Drug Delivery System, 2015, 30, 309-316.	0.0	2
41	Treatment of stroke with liposomal neuroprotective agents under cerebral ischemia conditions. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 97, 1-7.	4.3	51
42	Neuroprotective effect of nobiletin on cerebral ischemia/reperfusion injury in transient middle cerebral artery-occluded rats. Brain Research, 2014, 1559, 46-54.	2.2	76
43	Real-Time Trafficking of PEGylated Liposomes in the Rodent Focal Brain Ischemia Analyzed by Positron Emission Tomography. Artificial Organs, 2014, 38, 662-666.	1.9	31
44	Suppression in mice of immunosurveillance against PEGylated liposomes by encapsulated doxorubicin. Journal of Controlled Release, 2014, 192, 167-173.	9.9	19
45	Treatment of cerebral ischemia/reperfusion injury with PEGylated liposomes encapsulating FK506. FASEB Journal, 2013, 27, 1362-1370.	0.5	68
46	Nanoparticles accumulate in ischemic core and penumbra region even when cerebral perfusion is reduced. Biochemical and Biophysical Research Communications, 2013, 430, 1201-1205.	2.1	30
47	A single injection of liposomal asialo-erythropoietin improves motor function deficit caused by cerebral ischemia/reperfusion. International Journal of Pharmaceutics, 2012, 439, 269-274.	5.2	35
48	Amelioration of cerebral ischemia/reperfusion injury based on liposomal drug delivery system with asialo-erythropoietin. Journal of Controlled Release, 2012, 160, 81-87.	9.9	98